RÉSUMÉ
BACKGROUND: Politicization and misinformation or disinformation of unproven COVID-19 therapies have resulted in communication challenges in presenting science to the public, especially in times of heightened public trepidation and uncertainty. OBJECTIVE: This study aims to examine how scientific evidence and uncertainty were portrayed in US news on 3 unproven COVID-19 therapeutics, prior to the development of proven therapeutics and vaccines. METHODS: We conducted a media analysis of unproven COVID-19 therapeutics in early 2020. A total of 479 discussions of unproven COVID-19 therapeutics (hydroxychloroquine, remdesivir, and convalescent plasma) in traditional and online US news reports from January 1, 2020, to July 30, 2020, were systematically analyzed for theme, scientific evidence, evidence details and limitations, safety, efficacy, and sources of authority. RESULTS: The majority of discussions included scientific evidence (n=322, 67%) although only 24% (n=116) of them mentioned publications. "Government" was the most frequently named source of authority for safety and efficacy claims on remdesivir (n=43, 35%) while "expert" claims were mostly mentioned for convalescent plasma (n=22, 38%). Most claims on hydroxychloroquine (n=236, 79%) were offered by a "prominent person," of which 97% (n=230) were from former US President Trump. Despite the inclusion of scientific evidence, many claims of the safety and efficacy were made by nonexperts. Few news reports expressed scientific uncertainty in discussions of unproven COVID-19 therapeutics as limitations of evidence were infrequently included in the body of news reports (n=125, 26%) and rarely found in headlines (n=2, 2%) or lead paragraphs (n=9, 9%; P<.001). CONCLUSIONS: These results highlight that while scientific evidence is discussed relatively frequently in news reports, scientific uncertainty is infrequently reported and rarely found in prominent headlines and lead paragraphs.
Sujet(s)
AMP , Alanine , Traitements médicamenteux de la COVID-19 , Sérothérapie COVID-19 , Hydroxychloroquine , Humains , Incertitude , Alanine/analogues et dérivés , Alanine/usage thérapeutique , États-Unis/épidémiologie , AMP/analogues et dérivés , AMP/usage thérapeutique , Hydroxychloroquine/usage thérapeutique , Immunisation passive , COVID-19/épidémiologie , COVID-19/prévention et contrôle , Mass-médias , Antiviraux/usage thérapeutique , Médecine factuelle , SARS-CoV-2RÉSUMÉ
Newborns and young infants are at risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection. Passive immunity is the mainstay of infection prevention in this cohort. Transplacental transfer of maternal antibodies provides the newborn with immediate protection from life-threatening infections, however, is dependent upon gestational age, birth weight, mother's age, recent maternal vaccination, maternal nutritional status, maternal immunocompetence and medical conditions, and placental integrity. Efficient transplacental transfer of RSV-neutralizing antibodies have led to the development and approval of maternal RSV immunization for the protection of the newborn. Additionally, administration of RSV-specific antibodies to infants leads to high serum titers of RSV-neutralizing antibodies and further protection from severe disease.
Sujet(s)
Anticorps antiviraux , Immunité acquise d'origine maternelle , Immunisation passive , Infections à virus respiratoire syncytial , Humains , Infections à virus respiratoire syncytial/prévention et contrôle , Infections à virus respiratoire syncytial/immunologie , Immunisation passive/méthodes , Nouveau-né , Nourrisson , Femelle , Anticorps antiviraux/sang , Anticorps neutralisants/sang , Anticorps neutralisants/immunologie , Virus respiratoire syncytial humain/immunologie , Grossesse , Vaccins contre les virus respiratoires syncytiaux/immunologie , Vaccins contre les virus respiratoires syncytiaux/administration et posologieRÉSUMÉ
Egg yolk antibodies (IgY) can be prepared in large quantities and economically, and have potential value as polyvalent passive vaccines (against multiple bacteria) in aquaculture. This study prepared live and inactivated Vibrio fluvialis IgY and immunized Carassius auratus prior to infection with V. fluvialis and Aeromonas hydrophila. The results showed that the two IgY antibodies hold effective passive protective rates against V. fluvialis and A. hydrophila in C. auratus. Further, the serum of C. auratus recognized the two bacteria in vitro, with a decrease in the bacteria content of the kidney. The phagocytic activity of C. auratus plasma was enhanced, with a decrease in the expression of inflammatory and antioxidant factors. Pathological sections showed that the kidney, spleen, and intestinal tissue structures were intact, and apoptosis and DNA damage decreased in kidney cells. Moreover, the immunoprotection conferred by the live V. fluvialis IgY was higher than that of the inactivated IgY. Addition, live V. fluvialis immunity induced IgY antibodies against outer membrane proteins of V. fluvialis were more than inactivated V. fluvialis immunity. Furthermore, heterologous immune bacteria will not cause infection, so V. fluvialis can be used to immunize chickens to obtain a large amount of IgY antibody. These findings suggest that the passive immunization effect of live bacterial IgY antibody on fish is significantly better than that of inactivated bacterial antibody, and the live V. fluvialis IgY hold potential value as polyvalent passive vaccines in aquaculture.
Sujet(s)
Aeromonas hydrophila , Jaune d'Åuf , Maladies des poissons , Immunoglobulines , Infections à Vibrio , Vibrio , Animaux , Immunoglobulines/immunologie , Immunoglobulines/sang , Infections à Vibrio/médecine vétérinaire , Infections à Vibrio/immunologie , Infections à Vibrio/prévention et contrôle , Vibrio/immunologie , Maladies des poissons/immunologie , Maladies des poissons/prévention et contrôle , Jaune d'Åuf/immunologie , Aeromonas hydrophila/immunologie , Poisson rouge/immunologie , Infections bactériennes à Gram négatif/immunologie , Infections bactériennes à Gram négatif/médecine vétérinaire , Infections bactériennes à Gram négatif/prévention et contrôle , Anticorps antibactériens/sang , Anticorps antibactériens/immunologie , Immunisation passive/médecine vétérinaire , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologieRÉSUMÉ
This is the first report of the health economic benefits derived from preventing infections through Immunoglobulin Replacement Therapy (IgRT) in patients with secondary immunodeficiency due to hematological malignancies. We conducted a retrospective population-based cohort study using patient medical history and pharmacy data from the Hospital Clínico San Carlos for 21 patients between 2011 and 2020. The pharmacoeconomic impact of using prophylactic IgRT was assessed by comparing characteristics of the SID patients 1 year before and after initiating IgRT measured by direct medical and tangible indirect costs. Results indicate a marked reduction in hospitalization days following IgRT initiation, decreasing from an average of 13.9 to 6.1 days per patient, with the elimination of ICU admissions. While emergency department visits decreased significantly, the number of routine consultations remained unchanged. Notably, absenteeism from work dropped substantially. The financial analysis revealed significant reductions in medication use and fewer ancillary tests, resulting in considerable cost savings. Specifically, total expenditure dropped from 405,088.18 pre-IgRT to 295,804.42 post-IgRT-including the cost of IgRT itself at 156,309.60. Overall, the annual savings amounted to 109,283.84, validating the cost-effectiveness of IgRT in managing SID in patients with hematological cancers.
Sujet(s)
Analyse coût-bénéfice , Tumeurs hématologiques , Humains , Tumeurs hématologiques/thérapie , Tumeurs hématologiques/économie , Mâle , Femelle , Études rétrospectives , Adulte d'âge moyen , Adulte , Déficits immunitaires/économie , Déficits immunitaires/thérapie , Déficits immunitaires/traitement médicamenteux , Immunisation passive/économie , Sujet âgé , Coûts des soins de santé , Hospitalisation/économieRÉSUMÉ
OBJECTIVES: To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined. METHODS: We conducted a retrospective evaluation of our prospectively followed cohort of haematological patients treated with remdesivir for more than 10 days. Starting January 2023, upon COVID-19 diagnosis, the treatment strategy was based on symptoms and PCR cycle threshold (Ct) as follows: (i) when Ct was 25 or less or if the patient had symptoms, a course of remdesivir for at least 10 days, nirmatrelvir/ritonavir for 5 days (whenever possible) and convalescent plasma was administered; and (ii) when the patient was asymptomatic and had a PCR Ct of more than 25, when possible, a course of 5 days of nirmatrelvir/ritonavir was administered. The patient was considered to have achieved viral clearance and, thus, remdesivir was stopped, in either of these cases: (i) PCR negativity, or (ii) subgenomic RNA negativity. RESULTS: From January to November 2023, 18 patients benefited from a safe extended remdesivir administration, resulting in detection of SARS-CoV-2 viral clearance in a median time of 3.5 weeks (IQR 2.6-3.9) (min-max 1.6-8.0). No clinical or biological side effects were detected. No patient died or needed further treatment for their COVID-19 episode. CONCLUSIONS: The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.
Sujet(s)
AMP , Alanine , Antiviraux , Traitements médicamenteux de la COVID-19 , COVID-19 , Tumeurs hématologiques , Ritonavir , SARS-CoV-2 , Excrétion virale , Humains , Alanine/analogues et dérivés , Alanine/usage thérapeutique , Alanine/administration et posologie , Alanine/effets indésirables , AMP/analogues et dérivés , AMP/usage thérapeutique , AMP/effets indésirables , AMP/administration et posologie , Mâle , Femelle , Adulte d'âge moyen , Antiviraux/usage thérapeutique , Antiviraux/effets indésirables , Antiviraux/administration et posologie , Études rétrospectives , SARS-CoV-2/effets des médicaments et des substances chimiques , Sujet âgé , Ritonavir/usage thérapeutique , Ritonavir/effets indésirables , Ritonavir/administration et posologie , Tumeurs hématologiques/complications , Tumeurs hématologiques/traitement médicamenteux , Excrétion virale/effets des médicaments et des substances chimiques , Adulte , Résultat thérapeutique , Association médicamenteuse , Immunisation passive , Sérothérapie COVID-19RÉSUMÉ
This review article will summarize the vaccines and monoclonal antibodies currently under evaluation for the prevention of RSV disease in older infants, toddlers and young children. We will review the rationale for passive protection during the first months of life, and the role of active immunization afterwards, either with live attenuated, protein-based or mRNA vaccines.
Sujet(s)
Infections à virus respiratoire syncytial , Vaccins contre les virus respiratoires syncytiaux , Humains , Infections à virus respiratoire syncytial/prévention et contrôle , Infections à virus respiratoire syncytial/immunologie , Nourrisson , Vaccins contre les virus respiratoires syncytiaux/immunologie , Vaccins contre les virus respiratoires syncytiaux/usage thérapeutique , Enfant d'âge préscolaire , Immunisation passive , Anticorps monoclonaux/usage thérapeutique , Vaccins atténués/immunologie , Virus respiratoire syncytial humain/immunologieRÉSUMÉ
Long-acting passive immunization strategies are needed to protect immunosuppressed vulnerable groups from infectious diseases. To further explore this concept for COVID-19, we constructed Adeno-associated viral (AAV) vectors encoding the human variable regions of the SARS-CoV-2 neutralizing antibody, TRES6, fused to murine constant regions. An optimized vector construct was packaged in hepatotropic (AAV8) or myotropic (AAVMYO) AAV capsids and injected intravenously into syngeneic TRIANNI-mice. The highest TRES6 serum concentrations (511 µg/ml) were detected 24 weeks after injection of the myotropic vector particles and mean TRES6 serum concentrations remained above 100 µg/ml for at least one year. Anti-drug antibodies or TRES6-specific T cells were not detectable. After injection of the AAV8 particles, vector mRNA was detected in the liver, while the AAVMYO particles led to high vector mRNA levels in the heart and skeletal muscle. The analysis of the Fc-glycosylation pattern of the TRES6 serum antibodies revealed critical differences between the capsids that coincided with different binding activities to murine Fc-γ-receptors. Concomitantly, the vector-based immune prophylaxis led to protection against SARS-CoV-2 infection in K18-hACE2 mice. High and long-lasting expression levels, absence of anti-drug antibodies and favourable Fc-γ-receptor binding activities warrant further exploration of myotropic AAV vector-based delivery of antibodies and other biologicals.
Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , COVID-19 , Dependovirus , Vecteurs génétiques , Récepteurs du fragment Fc des IgG , SARS-CoV-2 , Animaux , Dependovirus/génétique , SARS-CoV-2/immunologie , SARS-CoV-2/génétique , SARS-CoV-2/métabolisme , Souris , Humains , COVID-19/immunologie , COVID-19/prévention et contrôle , Vecteurs génétiques/génétique , Anticorps neutralisants/immunologie , Anticorps antiviraux/immunologie , Anticorps antiviraux/sang , Récepteurs du fragment Fc des IgG/métabolisme , Récepteurs du fragment Fc des IgG/génétique , Récepteurs du fragment Fc des IgG/immunologie , Tropisme viral , Immunisation passiveRÉSUMÉ
The objectives of this study were to conduct a survey of failure-of-passive-transfer (FPT) in eastern Hokkaido Japan, to evaluate the association between herd-level FPT and death and culling or treatment, and to test the effectiveness of monitoring using herd-level FPT. A total of 4,411 Holstein and Holstein-Wagyu crossbreds calves born from Holstein dams during the year beginning April 2, 2019 on 39 dairy farms were included in the study to investigate death-and-culling and the treatment rate during the first month of life, as well as rearing management up to 3 weeks of age. A subset of Holsteins (n=381) was included in the study for passive transfer and farms were diagnosed as having FPT if more than 20% of newborn calves had serum IgG levels below 10 g/L at the herd level. The prevalence of FPT (Sujet(s)
Industrie laitière
, Immunoglobuline G
, Animaux
, Bovins
, Japon
, Immunoglobuline G/sang
, Femelle
, Immunité acquise d'origine maternelle
, Immunisation passive/médecine vétérinaire
, Maladies des bovins/épidémiologie
, Maladies des bovins/sang
, Animaux nouveau-nés
RÉSUMÉ
BACKGROUND: Although antiretroviral therapy (ART) effectively halts disease progression in HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong adherence required by ART highlight the imperative need for alternative therapeutic and preventative approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative, and possibly curative interventions against HIV infection. OBJECTIVE: This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1-infected individuals. MAIN FINDINGS: Recent findings from clinical trials have highlighted the potential of bNAbs in the treatment, prevention, and quest for an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effectively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization with bNAb has provided a "proof of concept" for antibody-mediated prevention against HIV-1 acquisition, although complete prevention has not been obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.
Sujet(s)
Anticorps neutralisants , Anticorps anti-VIH , Infections à VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Humains , Infections à VIH/immunologie , Infections à VIH/traitement médicamenteux , Infections à VIH/prévention et contrôle , Infections à VIH/virologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/immunologie , Anticorps anti-VIH/immunologie , Anticorps anti-VIH/usage thérapeutique , Anticorps neutralisants/immunologie , Anticorps neutralisants/usage thérapeutique , Immunisation passive/méthodes , Anticorps neutralisants à large spectre/immunologie , Anticorps neutralisants à large spectre/usage thérapeutique , Agents antiVIH/usage thérapeutique , AnimauxRÉSUMÉ
BACKGROUND: There is a need to understand the relationship between COVID-19 Convalescent Plasma (CCP) anti-SARS-CoV-2 IgG levels and clinical outcomes to optimize CCP use. This study aims to evaluate the relationship between recipient baseline clinical status, clinical outcomes, and CCP antibody levels. METHODS: The study analyzed data from the COMPILE study, a meta-analysis of pooled individual patient data from 8 randomized clinical trials (RCTs) assessing the efficacy of CCP vs. control, in adults hospitalized for COVID-19 who were not receiving mechanical ventilation at randomization. SARS-CoV-2 IgG levels, referred to as 'dose' of CCP treatment, were retrospectively measured in donor sera or the administered CCP, semi-quantitatively using the VITROS Anti-SARS-CoV-2 IgG chemiluminescent immunoassay (Ortho-Clinical Diagnostics) with a signal-to-cutoff ratio (S/Co). The association between CCP dose and outcomes was investigated, treating dose as either continuous or categorized (higher vs. lower vs. control), stratified by recipient oxygen supplementation status at presentation. RESULTS: A total of 1714 participants were included in the study, 1138 control- and 576 CCP-treated patients for whom donor CCP anti-SARS-CoV2 antibody levels were available from the COMPILE study. For participants not receiving oxygen supplementation at baseline, higher-dose CCP (/control) was associated with a reduced risk of ventilation or death at day 14 (OR = 0.19, 95% CrI: [0.02, 1.70], posterior probability Pr(OR < 1) = 0.93) and day 28 mortality (OR = 0.27 [0.02, 2.53], Pr(OR < 1) = 0.87), compared to lower-dose CCP (/control) (ventilation or death at day 14 OR = 0.79 [0.07, 6.87], Pr(OR < 1) = 0.58; and day 28 mortality OR = 1.11 [0.10, 10.49], Pr(OR < 1) = 0.46), exhibiting a consistently positive CCP dose effect on clinical outcomes. For participants receiving oxygen at baseline, the dose-outcome relationship was less clear, although a potential benefit for day 28 mortality was observed with higher-dose CCP (/control) (OR = 0.66 [0.36, 1.13], Pr(OR < 1) = 0.93) compared to lower-dose CCP (/control) (OR = 1.14 [0.73, 1.78], Pr(OR < 1) = 0.28). CONCLUSION: Higher-dose CCP is associated with its effectiveness in patients not initially receiving oxygen supplementation, however, further research is needed to understand the interplay between CCP anti-SARS-CoV-2 IgG levels and clinical outcome in COVID-19 patients initially receiving oxygen supplementation.
Sujet(s)
Anticorps antiviraux , Sérothérapie COVID-19 , COVID-19 , Immunisation passive , Immunoglobuline G , SARS-CoV-2 , Humains , COVID-19/thérapie , COVID-19/immunologie , COVID-19/mortalité , Anticorps antiviraux/sang , SARS-CoV-2/immunologie , Mâle , Adulte d'âge moyen , Femelle , Immunoglobuline G/sang , Sujet âgé , Résultat thérapeutique , Adulte , Études rétrospectives , Essais contrôlés randomisés comme sujetRÉSUMÉ
ABSTRACT: Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) can develop hypogammaglobulinemia, a form of secondary immune deficiency (SID), from the disease and treatments. Patients with hypogammaglobulinemia with recurrent infections may benefit from immunoglobulin replacement therapy (IgRT). This study evaluated patterns of immunoglobulin G (IgG) testing and the effectiveness of IgRT in real-world patients with CLL or NHL. A retrospective, longitudinal study was conducted among adult patients diagnosed with CLL or NHL. Clinical data from the Massachusetts General Brigham Research Patient Data Registry were used. IgG testing, infections, and antimicrobial use were compared before vs 3, 6, and 12 months after IgRT initiation. Generalized estimating equation logistic regression models were used to estimate odds ratios, 95% confidence intervals, and P values. The study population included 17 192 patients (CLL: n = 3960; median age, 68 years; NHL: n = 13 232; median age, 64 years). In the CLL and NHL cohorts, 67% and 51.2% had IgG testing, and 6.5% and 4.7% received IgRT, respectively. After IgRT initiation, the proportion of patients with hypogammaglobulinemia, the odds of infections or severe infections, and associated antimicrobial use, decreased significantly. Increased frequency of IgG testing was associated with a significantly lower likelihood of severe infection. In conclusion, in real-world patients with CLL or NHL, IgRT was associated with significant reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobials. Optimizing IgG testing and IgRT are warranted for the comprehensive management of SID in patients with CLL or NHL.
Sujet(s)
Immunoglobuline G , Leucémie chronique lymphocytaire à cellules B , Lymphome malin non hodgkinien , Humains , Leucémie chronique lymphocytaire à cellules B/complications , Leucémie chronique lymphocytaire à cellules B/thérapie , Sujet âgé , Adulte d'âge moyen , Mâle , Femelle , Immunoglobuline G/sang , Lymphome malin non hodgkinien/thérapie , Lymphome malin non hodgkinien/complications , Études rétrospectives , Infections/étiologie , Agammaglobulinémie/complications , Agammaglobulinémie/thérapie , Agammaglobulinémie/étiologie , Résultat thérapeutique , Études longitudinales , Sujet âgé de 80 ans ou plus , Adulte , Immunisation passive/méthodesRÉSUMÉ
Convalescent plasma was proposed for passive immunization against COVID-19; but so far there are conflicting results and still open questions. However, besides antibodies, other plasma proteins may be good candidates for further research and application. Thromboinflammation frequently complicates severe COVID-19, and classical anticoagulants like heparins seem to have limited effect. The natural protease inhibitors antithrombin III (ATIII), α1-antitrypsin (α1-AT) and α2-macroglobulin (α2-M), which are found decreased in severe COVD-19, play a crucial role in prothrombotic and inflammatory pathways. While ATIII and α1-AT are licensed as commercially prepared therapeutic concentrates, there is no preparation of α2-M available. The diagnostic, prognostic, and even therapeutic potential of plasma protease inhibitors should be further explored.
Sujet(s)
Anticoagulants , COVID-19 , SARS-CoV-2 , Humains , COVID-19/immunologie , COVID-19/sang , Anticoagulants/usage thérapeutique , SARS-CoV-2/immunologie , Sérothérapie COVID-19 , Immunisation passive/méthodes , alpha-1-Antitrypsine/usage thérapeutique , Antithrombine-III , alpha 2-Macroglobulines associées à la grossesseRÉSUMÉ
INTRODUCTION: When a new disease occurs, one of the most affordable remedies is drugs containing specific antibodies to this infectious agent. The use of such drugs is aimed at reducing the amount of the pathogen in the macroorganism and the associated reduction in the severity of the symptoms of the disease or recovery. The purpose of this review is to analyze the experience of using immunoglobulins and monoclonal antibodies in the treatment of COVID-19 patients during the pandemic. RESULTS AND CONCLUSION: The two main groups of medical protective agents that block the penetration of the SARS-CoV-2 virus into permissive cells are drugs obtained from blood plasma of convalescents (immunoglobulin) and human monoclonal antibodies. The first group of drugs in the treatment of COVID-19 includes blood plasma of convalescents, which can be successfully used for emergency prevention. The main disadvantage of using blood plasma convalescents is the difficulty of standardization due to the different content of specific antibodies in donors. Another disadvantage is the undesirable side effects in recipients that occur after plasma administration. An alternative approach to COVID-19 therapy is the use of humanized and genetically engineered human monoclonal antibodies against certain epitopes of the SARS-CoV-2 virus. For example, monoclonal antibodies against receptor-binding domain of the S-protein, which prevents the virus from entering permissive cells and interrupts the development of infection. The advantages of these drugs are their safety, high specific activity, and the possibility of standardization. However, the complexity of their production and high cost make them inaccessible for mass use in practical medicine.
Sujet(s)
Anticorps monoclonaux , COVID-19 , SARS-CoV-2 , Humains , SARS-CoV-2/immunologie , SARS-CoV-2/effets des médicaments et des substances chimiques , COVID-19/immunologie , COVID-19/thérapie , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux/immunologie , Anticorps antiviraux/immunologie , Anticorps antiviraux/usage thérapeutique , Immunoglobulines/usage thérapeutique , Immunoglobulines/immunologie , Traitements médicamenteux de la COVID-19 , Sérothérapie COVID-19 , Immunisation passive , Pandémies , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux humanisés/immunologie , Antiviraux/usage thérapeutiqueRÉSUMÉ
Adaptive immunity to viral infections requires time to neutralize and clear viruses to resolve infection. Fast growing and pathogenic viruses are quickly established, are highly transmissible and cause significant disease burden making it difficult to mount effective responses, thereby prolonging infection. Antibody-based passive immunotherapies can provide initial protection during acute infection, assist in mounting an adaptive immune response, or provide protection for those who are immune suppressed or immune deficient. Historically, plasma-derived antibodies have demonstrated some success in treating diseases caused by viral pathogens; nonetheless, limitations in access to product and antibody titer reduce success of this treatment modality. Monoclonal antibodies (mAbs) have proven an effective alternative, as it is possible to manufacture highly potent and specific mAbs against viral targets on an industrial scale. As a result, innovative technologies to discover, engineer and manufacture specific and potent antibodies have become an essential part of the first line of treatment in pathogenic viral infections. However, a mAb targeting a specific epitope will allow escape variants to outgrow, causing new variant strains to become dominant and resistant to treatment with that mAb. Methods to mitigate escape have included combining mAbs into cocktails, creating bi-specific or antibody drug conjugates but these strategies have also been challenged by the potential development of escape mutations. New technologies in developing antibodies made as recombinant polyclonal drugs can integrate the strength of poly-specific antibody responses to prevent mutational escape, while also incorporating antibody engineering to prevent antibody dependent enhancement and direct adaptive immune responses.
Sujet(s)
Anticorps monoclonaux , Anticorps antiviraux , Humains , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux/immunologie , Anticorps antiviraux/usage thérapeutique , Anticorps antiviraux/immunologie , Animaux , Maladies transmissibles/immunologie , Maladies transmissibles/thérapie , Maladies transmissibles/traitement médicamenteux , Maladies virales/immunologie , Maladies virales/thérapie , Maladies virales/traitement médicamenteux , Immunisation passive/méthodes , Anticorps neutralisants/immunologie , Anticorps neutralisants/usage thérapeutiqueRÉSUMÉ
Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS-CoV-2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS-CoV-2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID-19 infection. Here, we report on a series of 21 immunocompromised patients with COVID-19-most of them hematologic malignancies-treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS-CoV-2-antibody-containing plasma could clear SARS-CoV-2 infection in 16 out of 21 immunocompromised patients even if COVID-19-specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS-CoV-2 infection. Ten patients were major responders defined as an increase delta(d)Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS-CoV-2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10-24.25) to a median value of 29.57 (IQR = 27.55-34.63; p = <.0001) in the major response subgroup. Furthermore, when treated a second time with C/VP, even 4 out of 5 of the initial nonresponders showed an increase in Ct-values from a median value of 23.13 (IQR = 17.75-28.05) to a median value of 32.79 (IQR = 31.75-33.75; p = .013). Our results suggest that C/VP could be a feasible treatment of COVID-19 infection in patients with hematologic malignancies who did not respond to antiviral treatment.
Sujet(s)
Sérothérapie COVID-19 , COVID-19 , Tumeurs hématologiques , Immunisation passive , Sujet immunodéprimé , SARS-CoV-2 , Humains , COVID-19/immunologie , COVID-19/virologie , COVID-19/prévention et contrôle , COVID-19/thérapie , Tumeurs hématologiques/thérapie , Tumeurs hématologiques/immunologie , Tumeurs hématologiques/virologie , Femelle , Adulte d'âge moyen , Mâle , Sujet âgé , SARS-CoV-2/immunologie , Immunisation passive/méthodes , Sujet immunodéprimé/immunologie , Adulte , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Vaccins contre la COVID-19/immunologie , Vaccins contre la COVID-19/administration et posologie , Maladie chronique , Résultat thérapeutiqueRÉSUMÉ
Passive immunotherapy with specific antibodies targeting Amyloid ß (Aß) peptide or tubulin-associated unit (tau) protein has emerged as a promising therapeutic approach in Alzheimer's disease (AD). However, in a recent phase III clinical study, Sperling et al. (N Engl J Med 10.1056/NEJMoa2305032, 2023) reported that solanezumab, a monoclonal antibody targeting Aß peptide, failed to slow cognitive decline in AD patients. Previously, three other anti-Aß antibodies, bapineuzumab, crenezumab, and gantenerumab, have also failed to show similar beneficial effects. In addition, three humanized antibodies targeting tau protein failed in their phase II trials. However, other anti-Aß antibodies, such as lecanemab (a humanized mAb binds to soluble Aß protofibrils), donanemab (a humanized mAb binds to insoluble, N-terminal truncated form of Aß peptides) and aducanumab (a human mAb binds to the aggregated form of Aß), have been shown to slow the decline of cognitive functions in early stage AD patients. The specific targets used in passive immunotherapy in these clinical trials may explain the divergent clinical outcomes. There are several challenges and limitations of passive immunotherapy using anti-Aß antibodies and long term longitudinal studies are needed to assess their efficacy, side effects and cost effectiveness in a wider spectrum of subjects, from pre-dementia to more advanced dementia. A combination therapeutic approach using both anti-Aß antibodies and other pharmaceutical agents should also be explored.
Sujet(s)
Maladie d'Alzheimer , Humains , Maladie d'Alzheimer/thérapie , Maladie d'Alzheimer/immunologie , Peptides bêta-amyloïdes/métabolisme , Peptides bêta-amyloïdes/immunologie , Anticorps monoclonaux/usage thérapeutique , Immunisation passiveRÉSUMÉ
BACKGROUND AND OBJECTIVES: Initial therapeutic efforts to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included the use of plasma from convalescent donors containing anti-SARS-CoV-2 antibodies. High-neutralizing antibody titres are required for therapeutic efficacy. This study aims to show that immunoadsorption followed by tangential flow filtration can be used to obtain antibody concentrates with high-neutralizing capacities. MATERIALS AND METHODS: Eligible donors (n = 10, five males and three females) underwent immunoadsorption using adsorber columns specific for human antibodies. Glycine-washed out eluates of 1.5 L volume were further concentrated by tangential flow filtration using 30 kDa ultrafiltration membranes. The same membranes were applied for diafiltrations to exchange residual glycine for 0.9% normal saline. RESULTS: Antibody concentrates were obtained within 8 h from the start of donation and had 4.58 ± 1.95, 3.28 ± 1.28 and 2.02 ± 0.92 times higher total IgG, IgA and IgM concentrations, 3.29 ± 1.62 and 3.74 ± 0.6 times higher SARS-CoV-2 N and S antibody concentrations and 3.85 ± 1.71 times higher SARS-CoV-2 S-specific IgG concentrations compared to the donors' peripheral blood. The specific SARS-CoV-2 virus neutralization capacities increased in all but one concentrate. All antibody concentrates (50-70 mL final volume) passed microbiological tests, were free of hazardous glycine levels and could be stored at -80°C and 4°C for 1 year with 20 ± 3% antibody loss. CONCLUSION: Immunoadsorption followed by tangential flow filtration is a feasible procedure to collect IgG, IgA and IgM as well as SARS-CoV-2 N- and S-specific antibody concentrates of low volume, free of albumin and coagulation factors. Whether these concentrates can be used as passive immunisation in infected patients remains to be elucidated.
Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , COVID-19 , SARS-CoV-2 , Humains , COVID-19/thérapie , COVID-19/immunologie , COVID-19/sang , Mâle , SARS-CoV-2/immunologie , Femelle , Anticorps antiviraux/sang , Anticorps neutralisants/sang , Anticorps neutralisants/immunologie , Adulte , Techniques d'immunoadsorption , Adulte d'âge moyen , Donneurs de sang , Pandémies , Immunoglobuline G/sang , Sérothérapie COVID-19 , Immunoglobuline M/sang , Immunisation passiveRÉSUMÉ
An acute aseptic meningitis has been occasionally observed on intravenous polyclonal human immunoglobulin therapy. Since case reports cannot be employed to draw inferences about the relationships between immunoglobulin therapy and meningitis, we conducted a systematic review and meta-analysis of the literature. Eligible were cases, case series, and pharmacovigilance studies. We found 71 individually documented cases (36 individuals ≤ 18 years of age) of meningitis. Ninety percent of cases presented ≤ 3 days after initiating immunoglobulin therapy and recovered within ≤ 7 days (with a shorter disease duration in children: ≤ 3 days in 29 (94%) cases). In 22 (31%) instances, the authors noted a link between the onset of meningitis and a rapid intravenous infusion of immunoglobulins. Cerebrospinal fluid analysis revealed a predominantly neutrophilic (N = 46, 66%) pleocytosis. Recurrences after re-exposure were observed in eight (N = 11%) patients. Eight case series addressed the prevalence of meningitis in 4089 patients treated with immunoglobulins. A pooled prevalence of 0.6% was noted. Finally, pharmacovigilance data revealed that meningitis temporally associated with intravenous immunoglobulin therapy occurred with at least five different products. In conclusion, intravenous immunoglobulin may cause an acute aseptic meningitis. The clinical features remit rapidly after discontinuing the medication.
Sujet(s)
Immunoglobulines par voie veineuse , Méningite aseptique , Humains , Méningite aseptique/diagnostic , Méningite aseptique/étiologie , Méningite aseptique/thérapie , Immunoglobulines par voie veineuse/usage thérapeutique , Immunoglobulines par voie veineuse/effets indésirables , Immunoglobulines par voie veineuse/administration et posologie , Maladie aigüe , Enfant , Adolescent , Pharmacovigilance , Enfant d'âge préscolaire , Immunisation passive/méthodesRÉSUMÉ
Alzheimer's disease (AD) is the most common neurodegeneration having non-effective treatments. Vaccines or monoclonal antibodies are two typical immunotherapies for AD. Due to Aß neurotoxicity, most of the treatments target its generation and deposition. However, therapies that specifically target tau protein are also being investigated. UB311 vaccine generates N-terminal anti-Aß antibodies, that neutralize Aß toxicity and promote plaque clearance. It is designed to elicit specific B-cell and wide T-cell responses. ACC001 or PF05236806 vaccine has the same Aß fragment and QS21 as an adjuvant. CAD106 stimulates response against Aß1-6. However, Nasopharyngitis and injection site erythema are its side effects. AN1792, the first-generation vaccine was formulated in proinflammatory QS21 adjuvant. However, T-cell epitopes are omitted from the developed epitope AD vaccine with Aß1-42B-cell epitopes. The first-generation vaccine immune response was immensely successful in clearing Aß, but it was also sufficient to provoke meningoencephalitis. Immunotherapies have been at the forefront of these initiatives in recent years. The review covers the recent updates on active and passive immunotherapy for AD.